The subject of conditional approval and Priority review will be more clarified, and follow-up management will be strengthened. Previously, conditional approval regulations were in the notice, but it is expected that management and operation will be strengthened, including related contents in the Pharmaceutical Affairs Act, and procedural justification will be secured. The MFDS announced on the 19th that it had announced some amendments to the rules on drug safety.

The revision was prepared to stipulate detailed standards for matters delegated by the revised Pharmaceutical Affairs Act on July 20. The revised bill included ▲simplification of the sample collection procedure for drugs approved for shipmen